<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00957216</url>
  </required_header>
  <id_info>
    <org_study_id>08-129</org_study_id>
    <secondary_id>08-SAOA-001</secondary_id>
    <nct_id>NCT00957216</nct_id>
  </id_info>
  <brief_title>Coenzyme Q10 in Adult-Onset Ataxia</brief_title>
  <acronym>CoQATAX</acronym>
  <official_title>Safety and Tolerability of Coenzyme Q10 in Adult-Onset Sporadic Spinocerebellar Ataxia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Medical Branch, Galveston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Medical Branch, Galveston</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Physician-sponsored pilot study, whose purpose it is determine if high-dose oral&#xD;
      Coenzyme Q10 (CoQ10) is safe and tolerated in patients with sporadic forms of adult-onset&#xD;
      spinocerebellar ataxias (SAOA), a group of degenerative neurological disorders affecting the&#xD;
      cerebellum and pathways to and from the cerebellum, with or without additional central&#xD;
      nervous system (CNS) manifestations, in the absence of family history of degenerative&#xD;
      ataxias.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Physician-sponsored pilot study, whose purpose it is determine if high-dose oral&#xD;
      Coenzyme Q10 (CoQ10) is safe and tolerated in patients with sporadic forms of adult-onset&#xD;
      spinocerebellar ataxias (SAOA), a group of degenerative neurological disorders affecting the&#xD;
      cerebellum and pathways to and from the cerebellum, with or without additional central&#xD;
      nervous system (CNS) manifestations, in the absence of family history of degenerative&#xD;
      ataxias.&#xD;
&#xD;
      CoQ10 is an essential cofactor of the electron transport chain and is a potent free radical&#xD;
      scavenger in lipid and mitochondrial membranes. CoQ10 has shown efficacy in treatment of&#xD;
      Parkinson's disease patients, and a Huntington's disease trial gave a trend of slowing down&#xD;
      disease progression (CARE-HD). A small trial of CoQ10 in patients with Friedreich's ataxia&#xD;
      suggested potential beneficial effects on ventricular thickness. CoQ10 is being tested on ALS&#xD;
      patients and is considered to be potentially useful for treatment of Alzheimer's disease.&#xD;
      Thus, CoQ10 is considered to be a promising therapeutic agent that might slow down the&#xD;
      disease progression in a wide variety of neurodegenerative disorders. To date, very high&#xD;
      doses of CoQ10 have not been used in patients with ataxia and the safety and tolerability in&#xD;
      this group of patients should be established before efficacy trials are launched.&#xD;
&#xD;
      Twenty patients with SAOA will be recruited for a double-blind, randomized,&#xD;
      placebo-controlled, multicenter study. Fifteen patients will receive a total of 2400 mg of&#xD;
      oral CoQ10 daily, and five patients will receive placebo, for a period or 4 weeks. Cerebellar&#xD;
      functions will be measured using a validated rating scale (SARA), an oculomotor examination,&#xD;
      and functional measurement of motor function using a 9 hole peg test and timed walk. Safety&#xD;
      labs will be collected and a digital movie will be recorded at the beginning (prior to&#xD;
      treatment with CoQ10) and at the end of the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure cerebellar functions by a validated scale (SARA)</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Sporadic Ataxia</condition>
  <arm_group>
    <arm_group_label>sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Coenzyme Q10</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The CoQ10 arm will be compared with the placebo arm to determine if high-dose CoQ10 is safe and well tolerated in subjects with sporadic adult-onset spinocerebellar ataxias</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (sugar pill)</intervention_name>
    <description>placebo: 2 wafers 4 times a day</description>
    <arm_group_label>sugar pill</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Coenzyme Q10</intervention_name>
    <description>300mg wafers; 2 wafers 4 times a day</description>
    <arm_group_label>Coenzyme Q10</arm_group_label>
    <other_name>CoQ10</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of SAOA&#xD;
&#xD;
          2. Age 18 or older&#xD;
&#xD;
          3. Adult onset of ataxia&#xD;
&#xD;
          4. Ambulatory capability (with or without an assisting device)&#xD;
&#xD;
          5. Women with 2 years post menopause or surgical sterility or practicing adequate birth&#xD;
             control&#xD;
&#xD;
          6. Stable doses of psychotropic drugs&#xD;
&#xD;
          7. Stable doses of drugs for movement disorders&#xD;
&#xD;
          8. Ability to give informed consent&#xD;
&#xD;
          9. Ability to comply with trial procedures&#xD;
&#xD;
         10. Able to take oral medication&#xD;
&#xD;
         11. No active and significant systemic disease (cardiac, pulmonary, hepatic, renal disease&#xD;
             or cancer) that is not under adequate medical control&#xD;
&#xD;
         12. Women with child-bearing potential who have a negative urine pregnancy test and&#xD;
             practice adequate contraception during the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. A history or known sensitivity of intolerability to Coenzyme Q10&#xD;
&#xD;
          2. Diagnosis of secondary (non-degenerative) ataxia&#xD;
&#xD;
          3. Family history of degenerative ataxia&#xD;
&#xD;
          4. Diagnosis of childhood-onset ataxia&#xD;
&#xD;
          5. DNA diagnosis of inherited ataxia in the absence of family history&#xD;
&#xD;
          6. Other investigational agent within 30 days of screening&#xD;
&#xD;
          7. Ingestion of Coenzyme Q10 within 120 days of the baseline visit&#xD;
&#xD;
          8. Diagnosis of ongoing malignancy&#xD;
&#xD;
          9. Women who are pregnant or lactating or who have child bearing potential and not using&#xD;
             effective birth control&#xD;
&#xD;
         10. Uncontrolled hypertension&#xD;
&#xD;
         11. Symptomatic orthostatic hypotension&#xD;
&#xD;
         12. Uncontrolled diabetes mellitus&#xD;
&#xD;
         13. Untreated thyroid disease&#xD;
&#xD;
         14. Major psychiatric disease within 12 months of screening&#xD;
&#xD;
         15. History of non-compliance with other therapies&#xD;
&#xD;
         16. Drug or alcohol abuse within 12 months of screening&#xD;
&#xD;
         17. Other condition or therapy that may prevent participation in the opinion of the&#xD;
             investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sankarasubramoney H Subramony, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Medical Branch, Galveston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Universtity of Texas, Galveston</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555-0539</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <study_first_submitted>June 22, 2009</study_first_submitted>
  <study_first_submitted_qc>August 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2009</study_first_posted>
  <last_update_submitted>July 9, 2018</last_update_submitted>
  <last_update_submitted_qc>July 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult onset ataxia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ataxia</mesh_term>
    <mesh_term>Cerebellar Ataxia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ubiquinone</mesh_term>
    <mesh_term>Coenzyme Q10</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

